See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
p53 Invest is a Norwegian healthcare investment company, part of the family-owned TD Veen group, that identifies and invests in innovative healthcare companies — particularly in biotechnology and medical devices — that think new and disrupt the status quo. The firm seeks to contribute to the development and commercialization of groundbreaking ideas that transform people's lives, increase accessibility to cutting-edge treatments, and create exceptional value for patients. A typical p53 company is founded on strong science and technologies, is uniquely positioned and well-differentiated globally, and is led by passionate entrepreneurs with outstanding knowledge and high integrity. Beyond long-term capital, p53 acts as an active owner — preferably alongside like-minded co-investors — contributing knowledge, experience, and network through board participation and close collaboration with management.
Notable quotes
“Sarsia and p53 strive to bring cutting edge ideas and therapies from early-phase to clinical development and beyond to benefit patients and transform people's lives. Calluna Pharma epitomizes this, and we are enthusiastic to join forces with Forbion and to contribute to the success of this new entity.”
“We are proud to support Teitur Trophics' €28M Series A financing. Neurodegenerative diseases have a detrimental impact on millions of people's lives around the world, with serious implications for patients and their families.”
“P53 has been backing [Arxx Therapeutics] back since 2018, and the subsequent [Calluna Pharma deal] is a considerable milestone. This deal epitomizes what we seek to accomplish in p53: to contribute to the development and commercialization of ground-breaking ideas that transform people's lives, increase accessibility to cutting-edge treatments and innovative healthcare solutions and create exceptional value for patients.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Serenatis Bio | Pre-seed | — | 2025 |
| Valink Therapeutics | Pre-Series A | $12m | 2025-10-20 |
| Calluna Pharma | Series A | $82m | 2024-01-23 |
| Teitur Trophics | Series A | $31m | 2023-03-14 |
| Arxx Therapeutics | Seed | — | 2018 |
| Nykode Therapeutics | Seed | — | 2018 |
| Atai Life Sciences | Seed | — | 2019 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Sarsia | 2 |
| Forbion | 2 |
| Investinor | 2 |
| RV Invest | 1 |
| Sunstone Life Science Ventures | 1 |
| Industrifonden | 1 |
Fit check
Is p53 Invest a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit